

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): April 30, 2025

**EMERGENT BIOSOLUTIONS INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-33137**  
(Commission File Number)

**14-1902018**  
(IRS Employer  
Identification No.)

**300 Professional Drive,  
Gaithersburg, Maryland 20879**

(Address of principal executive offices, including zip code)

**(240) 631-3200**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	EBS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On April 30, 2025, Emergent BioSolutions Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 36,140,808 shares of the Company’s common stock were present or represented by proxy, which represented approximately 67% of the Company’s 54,337,026 shares of common stock that were outstanding and entitled to vote at the Annual Meeting as of the record date of March 3, 2025. Stockholders considered the three proposals outlined below, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A related to the Annual Meeting, which was filed with the United States Securities and Exchange Commission on March 21, 2025.

*Proposal 1.* To elect three Class I directors to hold office for a term expiring at our 2028 annual meeting of stockholders, each to serve until their respective successors are duly elected and qualified. All director nominees were elected and qualified. The voting results were as follows:

<b><u>Director Nominee</u></b>	<b><u>For</u></b>	<b><u>Withhold</u></b>	<b><u>Broker Non-Votes</u></b>
Keith Katkin	21,684,528	1,094,567	13,361,713
Ronald Richard	18,116,845	4,662,250	13,361,713
Kathryn Zoon, Ph.D.	21,779,200	999,895	13,361,713

*Proposal 2.* To ratify the appointment by the Audit and Finance Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Proposal 2 was approved. The voting results were as follows:

<b><u>For</u></b>	<b><u>Against</u></b>	<b><u>Abstentions</u></b>	<b><u>Broker Non-Votes</u></b>
34,773,959	1,152,704	214,145	—

*Proposal 3.* To approve, on an advisory basis, the 2024 compensation of the Company’s named executive officers. Proposal 3 was approved. The voting results were as follows:

<b><u>For</u></b>	<b><u>Against</u></b>	<b><u>Abstentions</u></b>	<b><u>Broker Non-Votes</u></b>
18,928,777	3,537,501	312,817	13,361,713

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**EMERGENT BIOSOLUTIONS INC.**

Dated: May 6, 2025

By: /s/ RICHARD S. LINDAHL

Name: Richard S. Lindahl

Title: Executive Vice President, Chief Financial  
Officer and Treasurer